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Abstract
Type 2 diabetes is still rapidly on the rise today, affecting 10.5% of individuals in the
United States between the ages 45 to 64 and 18.4% of those between the ages of 65 to 74. In the
past two decades, type 2 diabetes has doubled in all age groups. Many adults with type 2 diabetes
experience difficulty managing their blood sugars, which can result in a range of further
complications. One of the newest treatment options on the market today is a glucagon-like
peptide-1 (GLP-1) receptor agonist, Bydureon. Similar to Byetta, Bydureon has a main
ingredient of exenatide. It offers once a week dosing as opposed to twice-a-day, which may be
more appealing to patients.
The purpose of this study was to examine the efficacy of a newly FDA released
medication, Bydureon, once weekly dosage in adults with type 2 diabetes. A descriptive,
comparative, retrospective study of 35 patients evaluated efficacy by examining Hgb A1C and
body mass index in adults with type 2 diabetes at baseline and 3 months after Bydureon was
prescribed. Data were collected by a chart review of records in a primary care practice.
Results demonstrated a statistically significant difference between baseline to 3 month
means in both Hgb A1C (t (34)= -3.05, p=.0044) and BMI (t (34) = -2.86, p = .0072) for patients
using Bydureon.
Health care providers need to individualize the patients’ plans of care to address
multifactorial areas of their diabetes care and provide them with an opportunity to successfully
meet their goals. Practitioners must be knowledgeable about the treatment options available,
including the newer GLP-1 receptor agonist, Bydureon and its efficacy for adults with type 2
diabetes.

Chapter One: Introduction
Diabetes mellitus, more commonly referred to as diabetes, is a group of clinically
heterogeneous metabolic disorders that are commonly characterized by glucose intolerance
resulting from a defect in either the action and/or or secretion of insulin (Jones, Brashers, &
Huether, 2010). It is estimated that some 25.8 million people of all ages in the United States
(U.S.) have diabetes, approximately 8.3 percent of the total population (National Diabetes
Information Clearinghouse [NDIC], 2011). Of these 25.8 million, only 18.8 million people are
diagnosed. Diabetes is the seventh leading cause of death in the U.S. and one of the major causes
of heart disease, stroke, renal failure, non-traumatic lower-limb amputations, and blindness. It is
estimated that by 2030, the estimated worldwide population with diabetes will increase by 60
percent over the 2000 numbers (American Diabetes Association [ADA], 2012). This increase is
due to the general population aging, as well as the eating and physical activity habits in the
world, with a parallel increase in obesity (Van Dijk, et al., 2011).
Although there is no cure for diabetes, there are a variety of clinical management
strategies that can avoid or minimize complications, increase the survival rates, and improve
quality of life for the individual with diabetes (American Diabetes Association [ADA], 2012).
These strategies include patient education on management and monitoring of blood glucose
levels, and maintaining blood glucose within the normal range. A number of antidiabetic
medications have been developed to help individuals with type 2 diabetes achieve blood glucose
levels. The most recent of these medications are the incretin mimetics including exenatide.
Byetta, a twice daily subcutaneous dosage of exenatide was released by the FDA in April of
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2005 and its use has been on the rise since then. More recently, in January 2012, Bydureon, an
extended release dose of exenatide, was approved by the FDA (Exenatide, 2012).
Purpose
The purpose of this study was to examine the clinical efficacy of Bydureon, once weekly
dosage in adults with type 2 diabetes. This descriptive, comparative, retrospective study
evaluated medication efficacy by examining Hgb A1C and body mass index in adults with type 2
diabetes at baseline, and then at 3 months after Bydureon was prescribed. The research question
was:
Do adult patients with type 2 diabetes who are started on the once weekly dosage of Bydureon
have an improved Hgb A1C and BMI over a 3 month period?
Theoretical Framework
The conceptual framework that grounds this study is the health belief model, first
developed in 1935 by Kurt Lewin, the Gestalt psychologist (Rosenstock, Strecher, & Becker,
1988). Lewin developed the field theory of decision making and believed that people are viewed
as acting in a life space, which is the quantity of all the psychological factors imposing upon a
person at any given moment in time. In the 1950s, a group of social psychologists, including
Rosenstock, Hochbaum, and Kegels, working for the U.S. Public Health Services, focused on
making improvements in preventative health services. They further developed the health belief
model while trying to examine why individuals did not participate in prevention and screening
programs. In the 1970s and 1980s, this model was expanded by Becker, and the latest changes to
the model were done in 1988 (Rosenstock, et al., 1988). The health belief model has been
recommended as an applicable and appropriate model for health promotion in individuals with
diabetes (Gutierrez & Long, 2011).

3
The health belief model addresses an individual’s perception of the risk of a health
problem and the associated assessment of a recommended behavior for managing the problem,
which is manifested as a behavior (Rosenstock, et al., 1988). There are three major components
of the model: individual perceptions, modifying factors, and likelihood of action (See Figure
1.1). This specific conceptual framework is relevant because medication adherence is frequently
assessed and evaluated through the lens of the health belief model. It is apparent that in
individuals with diabetes, control is intimately linked to medication adherence, and control of the
disease is linked to clinical outcomes, and long-term complications such as renal failure,
amputations, diabetic ulcers, and blindness. Improving medication adherence results in tighter
glucose control, maximizing the potential for improved outcomes.
Figure 1.1

Figure 1.1. From “Basic Elements of the Health Belief Model,” by R. Ashford and A.S.
Blinkhorn, 1999, British Dental Journal, 186, p.436. Copyright 2012. Reprinted with
permission.
Individual Perceptions
Individual perceptions are those perceptions of one’s susceptibility to the disease or
condition and one’s perception of the seriousness of the disease or condition if one develops the
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condition (Rosenstock, et al., 1988). Perceived susceptibility is one’s opinion of the chances or
assessment of their risk for developing the condition, in this case, diabetes. In a diabetic
individual, perceived susceptibility is determining their beliefs regarding the results of
medication non-compliance.
Perceived severity is one’s opinion on the severity of a condition and its potential
consequences. In a diabetic individual, perceived severity is looking at their beliefs about the
severity of their health illness and resulting complications.
Modifying Factors
Modifying factors are demographic and psychosocial variables, perceived threat, and
cues to action. Demographics include the individual's age and sex, and psychosocial variables
include the individuals personality and social class. Perceived threat is the threat of diabetes
itself. Cues to action are factors that may be used to activate the willingness of the person and
stimulate the good behaviors. Cues of action stimulates the individuals readiness to act on their
given health plan or medication regimen (Kuhns & McEwen, 2011).
Likelihood of Action
Likelihood of action is the likelihood that the individual will take the plan of action and
follow through with it. This last component of the health belief model includes an examination of
the interplay between perceived benefits of and perceived barriers to the health promoting
behavior. Perceived benefits are one’s assessment of the positive consequences of adopting the
health behavior. In an individual with diabetes, perceived benefits are defined as the individual’s
overall health and their perception of how the medication regimen will benefit their overall
health (Kuhns & McEwen, 2011).
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Perceived barriers are one’s opinion of the tangible and psychological cost of the advised
action (Kuhns & McEwen, 2011). In an individual with diabetes, perceived barriers are the
individual's perception of the side effects of the medications, their long term effects, and the
difficulty of integrating the medication regimen into their daily life schedule.
Self-efficacy defines the confidence the individual feels in their ability to successfully
manage and maintain their health illness. It was introduced to address habitual unhealthy
behaviors and the challenges with respect to those behaviors (Kuhns & McEwen, 2011).
Definition of Terms
Diabetes Mellitus
Diabetes mellitus is a condition characterized by hyperglycemia resulting from the
body’s inability to utilize blood glucose for energy (Jones et al., 2010).
Type 2 diabetes
Type 2 diabetes is a condition characterized by high blood glucose levels or glucose
intolerance typically presenting in adulthood and exacerbated by obesity and an inactive
lifestyle. This condition results in either a lack of insulin secretion or the inability of the body to
use insulin efficiently (ADA, 2012).
Bydureon
Bydureon is a once-a-week dosed incretin mimetic medication used to reduce fasting and
postprandial glucose levels (Lippincott, 2012).
Hemoglobin A1C (Hgb A1C)
Hemoglobin A1C is a laboratory measure of an individual’s blood glucose level average
over a period of two to three months. It is a direct measure of the amount of glucose adhering to
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the red blood cell, which is directly proportional to the amount of glucose in the blood (ADA,
2012).

Body mass index (BMI)
Body mass index is a calculated measure used to evaluate body weight relative to a
person’s height and determines if a person is underweight, normal weight, overweight, or obese.
The formula for BMI is: Weight (lb) / (Height (in) x Height (in)) x 703 (ADA, 2012).
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Chapter Two: Review of Literature
This chapter begins with a basic overview of diabetes mellitus. Type 1 diabetes mellitus
is briefly discussed followed by a thorough discussion on type 2 diabetes mellitus, covering the
pathophysiology, prevalence, risk factors, clinical manifestations, evaluation, and treatment
including the new incretin mimetic medication, exenatide. Lastly, research on exenatide are
examined and summarized.
Diabetes Mellitus
Diabetes mellitus, more commonly referred to as diabetes, is not a single disease but a
group of clinically heterogeneous disorders that are classified by glucose intolerance (Jones, et
al., 2010). Diabetes consists of several different etiologies of disturbed glucose tolerance and
includes many causally unrelated diseases. Disturbance of carbohydrates, fats, and protein
metabolism characterizes diabetes as well as chronic hyperglycemia. There are four different
categories of diabetes; type 1; type 2; other specific types, generally associated with medications
and/or other conditions; and gestational diabetes, which is diabetes diagnosed in and confined to
the pregnancy period (ADA, 2012). The most common of the four are type 1 and type 2 diabetes
(see Table 2.1 for a general comparison).
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Table 2.1
Comparison of Type 1 and Type 2 Diabetes
Feature
Type 1 Diabetes
Type 2 Diabetes
Onset
Sudden
Gradual
Age at Onset
Mostly young
Mostly in adults
Body Habitus
Thin or normal
Often obese
Ketoacidosis
Common
Rare
Autoantibodies
Usually present
Absent
Endogenous insulin
Low or absent
Normal, decreased or increased
Concordance in
50%
90%
identical twins
90-95% of US diabetics
Prevalence
Less prevalent
From Comparison of type 1 and 2 diabetes. Information from http://www.diffen.com/ difference/
Type_1_Diabetes_vs_Type_2_Diabetes
Type 1 Diabetes
Type 1 diabetes, previously known as juvenile diabetes or insulin-dependent diabetes, is
the result of the absence of insulin production due to an autoimmune-mediated specific loss of
beta cells in the pancreatic islet. A genetic-environmental interaction is thought to be the cause of
type 1 diabetes, but it is still unclear. While diagnosed in both children and adults, diagnosis of
the disease is most commonly made at the age of 12 years with winter and fall seasonal
distribution. Type 1 diabetes mellitus affects 0.17 percent of children in the United States and 10
percent of all the people with diabetes. The staple in the pharmacologic management of type 1
diabetes is the self-administration of insulin (Jones, et al., 2010).
Type 2 Diabetes
The endocrine system is a complex network made up of integrated hormone-producing
glands and organs that produce and release various hormones to maintain and control important
functions in the body. In the case of diabetes, this network involves insufficient islet B-cell and
adipose-tissue responses to chronic fuel surplus, which results in a so-called nutrient spillover,
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resistance of insulin, and finally, overall metabolic stress. The final damage includes multiple
organs (Nolan, Damm, & Prentki, 2011).
In type 2 diabetes, the body either fails to produce sufficient insulin to meet the body’s
needs (decreased insulin secretion by beta cells) or insulin target cells ignore the insulin (insulin
resistance). In order for the body to utilize glucose for energy, insulin is necessary. When an
individual consumes food, the body breaks down all of the sugars and starches into glucose,
which is the basic fuel for the cells in the body. Insulin then transports glucose from the
bloodstream into the individual cells (Jones, et al, 2010).
Pathophysiology
There have been several different genes identified associated with type 2 diabetes. These
include genes that code for beta cell mass, beta cell function, proinsulin and insulin molecular
structure, insulin receptors, hepatic synthesis of glucose, glucagon synthesis, and cellular
responsiveness to insulin stimulation (Nolan, et al., 2011). In combination with environmental
influences, these genetic anomalies result in type 2 diabetes. Although many individuals with
risk factors for type 2 diabetes, such as obesity, metabolic syndrome, and hypertension are
insulin resistant, only those with a genetic predisposition will develop diabetes mellitus. A
suboptimal response of insulin-sensitive tissue to insulin is what defines insulin resistance.
Abnormality of the insulin molecule, high amounts of insulin antagonists, down-regulation of the
insulin receptor, decreased or abnormal activation of postreceptor kinases, and alteration of
glucose transporter proteins all are mechanisms involved in the abnormalities of the insulin
signaling pathways and contribute to insulin resistance (Jones, et al., 2010).
Obesity, a major contributor to insulin resistance, is noted in approximately 60 to 80
percent of individuals with type 2 diabetes. Obesity leads to an increased level of adipokines,
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hormones produced in adipose tissue, resulting in decreased insulin sensitivity. With a decreased
level of insulin sensitivity, there is high risk for developing type 2 diabetes. Also associated with
obesity are increased serum free fatty acid and intracellular deposits of triglycerides and
cholesterol, usually due to a high caloric and lipid intake. High caloric and lipid intake results in
interference with the signaling of intracellular insulin and decreases the responses to insulin in
the tissue, causing an alteration in the secretion of insulin within the beta cells, intra-abdominal
adipocytes are inflammatory cytokines that further contribute to insulin resistance (Jones, et al.,
2010).
An individual may have diabetes for many years with masking of clinical appearance due
to compensatory hyperinsulinemia. Compensatory hyperinsulinemia is when the body
compensates for a state of elevated insulin in the body. This is required to achieve and maintain a
sufficient degree of glycemic control (Edelman & Henry, 2002). Beta cells begin to dysfunction,
which then leads to an insulin activity deficiency. Beta cells go through cell exhaustion or
undergo cell death. As this process continues, patients then begin to present with some of the
clinical manifestations of the disease, and type 2 diabetes is then diagnosed (Jones, et al., 2010).
When the disease has gone on unrecognized for many years, complications, such as early stages
of microvascular and frank macrovascular disease may be present at the time of diagnosis
(Edelman & Henry, 2002).
Glucagon is a very important hormone in the endocrine system that is produced by the
alpha cells of the pancreas and acts in the liver to increase blood glucose by acting as an
antagonist to insulin. In type 2 diabetes, the pancreatic alpha cells are less responsive to glucose
inhibition, resulting in an increased glucagon secretion, resulting in increased hepatic glucose
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and subsequent hyperglycemia. Amylin, also released by the beta cells, inhibits functions to
inhibit glucagon secretion (Jones, et al., 2010).
Several peptides are involved in the processes of glucose metabolism. Incretins are
released from the gastrointestinal tract, in response to food intake, and increases the sensitivity of
beta cells to circulating glucose levels, thereby improving insulin responsiveness to meals. GLP1 is cleaved from proglucagon in the intestinal mucosa, and binds to receptors on beta cells,
increasing the synthesis and secretion of insulin in response to glucose levels. Another peptide
produced in the gastrointestinal tract and pancreatic islets cells is ghrelin. Ghrelin stimulates
growth hormone production; decreased levels of ghrelin have been associated with insulin
resistance and increased fasting insulin levels in individuals with type 2 diabetes (Jones, et al.,
2010).
Prevalence
Within the United States, type 2 diabetes accounts for approximately 90% of all diabetes
cases. Type 2 diabetes is most common among Latinos, Native Americans, Asian Americans,
African Americans, Native Hawaiians, other Pacific Islanders, and the aged population (ADA,
2012).
The incidence of type 2 diabetes has doubled in the past two decades. Although the
greatest increase has been seen among white men, type 2 diabetes diagnosis remains the most
common among black women. There has also been an increase in diagnosis among Native
American children aged 15 to 19 and in obese children worldwide (ADA, 2012).
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Risk Factors
The most well-recognized risk factors for type 2 diabetes are age, obesity, hypertension,
physical inactivity, and family history. Other risk factors still being investigated are elevated Creactive protein, decreased adiponectin, increased leptin, and increased interleukin 6 (IL-6)
(Jones, et al., 2010).
Clinical Manifestations
Type 2 diabetes often has nonspecific clinical manifestations. While this disease may
affect individuals younger than age 30 years, it typically afflicts individuals older than 30 years
of age. Some of the classic symptoms of type 2 diabetes are polyuria, an increase in urination;
polydipsia, an increase in thirst; and polyphagia, an increase in hunger (Edelman & Henry,
2002). Hunger is triggered by the decrease or depletion of insulin resulting in the inability to
transport glucose from the intravascular tissue into the cells depleting the muscles and organs of
an energy source. Although an individual may experience an increase in appetite in order to
satisfy their hunger, weight loss may be noted due to the inability to metabolize glucose affecting
utilization of alternative fuels stored in muscle and fat tissue.
Fatigue is also a common feature experienced in type 2 diabetes. Hyperglycemia results
in osmotic changes not only in the vasculature but within the ocular tissue as well resulting in
visual changes such as diminished visual acuity. Furthermore, type 2 diabetics may result in
delayed wound healing and frequent infections such as vaginal and urinary tract infections.
Individuals with type 2 diabetes may develop acanthosis nigricans, dark and velvety areas within
the folds and creases of the skin, typical of insulin resistance that is caused by changes in keratin
in the skin. The presence and severity of symptoms may vary from individual to individual or
may be entirely absent (Jones, et al., 2010).
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Evaluation
Diabetes should be suspected in the presence of any of the above signs and symptoms.
Clinicians should have a high index of suspicion of type 2 diabetes if multiple risk factors are
present, even in the absence of signs and symptoms. These individuals should be screened for
pre-diabetes, the condition in which an individual has either impaired fasting glucose or impaired
glucose tolerance (Edelman & Henry, 2002).
Laboratory evaluation may be a fasting plasma glucose, 2-hour oral glucose tolerance
test, and HgbA1c (Jones, et. al., 2010). These tests may be used to diagnose either pre-diabetes
or diabetes. Table 2.2 provides the laboratory differentiation between pre-diabetes and diabetes.
Pre-diabetes may be manifested as either impaired fasting glucose or impaired glucose
intolerance.
Table 2.2
Laboratory Evaluation for Diagnosis of Diabetes
Test
Values for Pre-diabetes
Random Blood Glucose Two random test greater or
equal to 140mg/dl but less
than 200mg/dl
Fasting Plasma Glucose 100mg/dl to 125mg/dl

Values for Diagnosis
Greater than or equal to 200
mg/dl

Greater than or equal to
126mg/dl
2-hour post-75Gm
140mg/dl to 199mg/dl
Greater than or equal to
Glucose Load
200mg/dl
Hgb A1C
5.7% to 6.4%
Greater than or equal to 6.5%
Information from “Diagnosis and Classification of Diabetes Mellitus,” by American Diabetes
Association, 2010, Diabetes Care, 33, pp.66-67.

Elevated fasting plasma glucose concentration, abnormal oral glucose tolerance test, and
symptoms such as polyuria, polydipsia, and polyphagia are included in the criteria for the
diagnosis of diabetes. Impaired glucose tolerance resembles diabetes mellitus in that it results
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from reduced suppression of hepatic glucose output and a reduction in the function of the
pancreatic islet cells. Similar to overt diabetes, individuals with impaired glucose tolerance are at
increased risk of cardiovascular disease and premature death (Jones, et al., 2010). These
individuals should be informed of their increased risk from their health care provider and should
be counseled on effective strategies, such as exercise and dieting, to decrease their risks. These
individuals should see their health care provider more frequently to have these tests completed
and continue close monitoring of diabetes. Persons, who are diagnosed with type 2 diabetes,
should be referred to an endocrinologist for follow up every three to six months for development
of a plan of care prescribed by the endocrinologist (ADA, 2010).
Treatment
Treatment of type 2 diabetes is a very important aspect in the overall management of type
2 diabetes. The goal of treatment is to restore near-euglycemia and correct related metabolic
disorders. Diet, exercise, and weight loss are an important adjunct to an appropriate medication
regimen. While caloric restrictions are the mainstay of an appropriate diet for the type 2 diabetic,
minimizing the consumption of refined carbohydrates including processed sugars should also be
incorporated as part of the diabetic regimen. A potential benefit of weight loss is a reduction in
insulin resistance and increase in insulin sensitivity further improving glucose control. Based on
the Medical Nutrition Therapy for Prevention and Treatment of Diabetes, each diet needs to be
individualized with a focus on reduction in fats and carbohydrates (Jones, et al., 2010).
Exercise is a very important aspect in individuals with type 2 diabetes. Exercise promotes
insulin sensitivity resulting in reductions in glucose levels as well as diminished medication
requirements (Nolan, et al., 2011). In addition, exercise reduces serum triglyceride and total
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cholesterol levels while increasing high-density lipoprotein levels, enhancing weight loss weight,
and an overall feeling of well-being.
When diet and exercise are ineffective in adequately managing diabetes, the use of
medications is indicated. Oral medications include sulfonylureas, biguandides,
thiazolidinediones, dipeptidyl peptidease-4 inhibitors, and α-glucosidase inhibitors.
Sulfonylureas are used to acutely supplement beta cell insulin secretion, whereas biguandides
prevent hepatic glucose production and increase the sensitivity of peripheral tissue to insulin.
Thiazolidinediones increase insulin sensitivity, especially in adipose tissue. DDP-IV inhibitors
increase GLP-1 levels that in turn increase insulin secretion. a-Glycosidase inhibitors delay
carbohydrate absorption in the gut and inhibit disaccharides and therefore decrease postprandial
hyperglycemia (Nathan, et al., 2009).
While traditionally reserved for use in later stages of type 2 diabetes, the early initiation
of exogenous insulin has become more common and suggested (Nathan, et al., 2009). Insulin
increases peripheral glucose utilization and therefore decreases hepatic glucose output and
lipolysis. Insulin may also be used in conjunction with various combinations of oral medications
(Krentz, Patel, & Bailey, 2008). More recently, the discovery of the incretin system has led to the
advent of a novel class of anti-diabetic medications known as the GLP-1 receptor agonists,
specifically extenatide (Campbell, 2011).
Exenatide
GLP-1 is an amino acid that enhances glucose-dependent insulin secretion as well as
other antihyperglycemic functions including suppressing glucagon secretion and delaying gastric
emptying thereby slowing carbohydrate absorption into the blood stream (Lippincott, 2012).
Exenatide, a GLP-1 receptor agonist, is an injectable synthetic formulation of exendin-4, a
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peptide derived from the saliva of the Gila monster. The amino acid sequence of exenatide
partially overlaps that of GLP-1 thereby mimicking the effects of GLP-1. GLP-1 activity helps to
improve glycemic control whenever blood glucose is elevated and in a fasting state, stimulates
glucose-dependent insulin secretion and suppresses inappropriate glucagon secretion, which then
decreases hepatic glucose production. In a nourished state, GLP-1 stimulates glucose-dependent
insulin secretion, suppresses postprandial glucagon secretion, which decreases hepatic glucose
production, improves first-phase insulin response, slows gastric emptying, and reduces food
intake (Bydureon, 2012).
Exenatide is contraindicated in patients with hypersensitivity to exenatide or its
components, type 1 diabetes or diabetic ketoacidosis, and individuals with end-stage renal
disease or severe gastrointestinal disease. While adequate studies of exenatide use during
pregnancy are limited, rat studies did result in fetal abnormalities. Thus, exenatide is a pregnancy
category C drug that should only be used during pregnancy if the potential benefit outweighs the
potential fetal risk. Furthermore, exenatide should be used cautiously during breastfeeding
(Lippincott, 2012).
Adverse reactions to exenatide include dizziness, headaches, weakness, anorexia,
diarrhea, dyspepsia, nausea, pancreatitis, vomiting, reflux, hypoglycemia, excessive sweating,
prutitis, urticaria, rash, injection site reaction, angioedema, and anaphylaxis. Common drug
interactions may include acetaminophen, digoxin, lisinopril, lovastatin, and sulfonylureas
(Lippincott, 2012).
Important considerations for exenatide involve assessing renal and gastrointestinal
function before and frequently during treatment (Exenatide, 2012). Glucose levels should be
monitored regularly and glycosylated hemoglobin levels obtained periodically. Exenatide should
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be discontinued if pancreatitis is suspected. When prescribing exenatide, the patient should be
informed of the risks of use as well as a review of the proper use and storage of dosage pen and
pen needles. The patient should be informed as to the timing of administration of exenatide with
respect to the morning and evening meal.
Patients should be made aware that exenatide may decrease appetite, food intake and
body weight and does not warrant a change in dosage. Individuals on exenatide need to be
educated that severe, persistent, unexplained abdominal pain or vomiting needs to be reported to
health care provider immediately. Steps for managing hypoglycemia need to be reviewed with
individuals taking exenatide. The storage of exenatide is very important and needs to be
reviewed with the individual. Patients should be educated on infection prevention of local site
injections (Exenatide, 2012).
Preparations
Exenatide is available in two preparations, Byetta and Bydureon. Byetta is prepared as 5
mcg/dose and 10 mcg/dose in 1.2 ml and 2.4 ml prefilled pens respectively. Byetta is
administered subcutaneously within 60 minutes before the morning and evening meals. The
individual is usually initiated on a 5 mcg subcutaneous dose twice daily and then escalated to a
10 mcg subcutaneous dose twice daily after one month. Byetta may be administered in the
traditional subcutaneous sites such as the thigh, abdomen, or upper arm. Furthermore, Byetta
should be stored in the refrigerator at 36 to 46 degrees Fahrenheit and should be discarded after
30 days, even if it is not completely empty (Exenatide, 2012).
Bydureon is the newly approved extended-release formulation of exenatide. Bydureon is
available as a single dose weekly injection of 2 mg. Bydureon is supplied as a self-contained kit
which includes a 2 mg dose of powdered Bydureon that is then suspended in an accompanying
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prefilled syringe of diluent before injection. This medication is administered once weekly and
can be administered at any time during the day, with or without meals, provided it is
administered the same day every week. Once again, this subcutaneous injection can be given in
the thigh, abdomen, or upper arm and should be stored in the refrigerator at 36 to 46 degrees
Fahrenheit and discarded after 30 days, even if it is not completely empty (Bydureon, 2012).
Research on Exenatide
A series of studies, called DURATION, have been completed. These studies examine the
efficacy of Byetta and/or Bydureon and/or other hypoglycemic agents.
DURATION-1 was a randomized, multicenter, comparator-controlled, open-label trial
that compared Byetta versus Bydureon in 295 patients with type 2 diabetes. This study focused
on Hgb A1C, fasting plasma glucose, and body weight. Bydureon elicited sustained
improvements in glycemic control and body weight throughout the 52-week study, and patients
who switched from Byetta to Bydureon experienced further improvements in Hgb A1C and
fasting plasma glucose (Buse, et al., 2010).
DURATION-2 compared the efficacy and safety of Bydureon versus Sitagliptin or
Pioglitazone as an adjunct to metformin for type 2 diabetics. This was a 26-week randomized,
double-blinded, double-dummy, superiority trial that included 514 participants. Addition of
Bydureon to metformin achieved the goal of optimal glucose control more than an addition of
maximum daily doses of either Sitagliptin or Pioglitazone (Bergenstal, et al., 2010).
DURATION-3 compared exenatide once weekly with insulin glargine in patients with
type 2 diabetes. This study was an open-label randomized trial that included 456 patients, 233 on
Exenatide and 223 on insulin glargine. Hgb A1C was monitored throughout this 26 week study
and the interpretation from this study was that Bydureon is an important therapeutic option for
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type 2 diabetics for whom risk of hypoglycemia, weight loss, and convenience are particular
concerns (Diamant, et al., 2010).
DURATION-4 compared the efficacy and safety of Bydureon versus metformin,
Pioglitazone, and Sitagliptin used as monotherapy in drug-naïve type 2 diabetic patients. There
were a total of 820 participants in this study that were monitored over 26 weeks in this doubleblind study. The results showed that Bydureon was non-inferior to metformin, but not
Pioglitazone and was superior to Sitagliptin with regards to reduction of Hgb A1C. Bydureon
and Metformin showed similar improvements in blood sugar control along with weight reduction
benefit and no increased risk of hypoglycemia (Russell-Jones, et al., 2011).
DURATION-5 compared the effects of once-weekly Bydureon versus twice daily, Byetta
for treatment of patients with type 2 diabetes. This study was conducted in 43 sites throughout
the United States, with 252 type 2 diabetic participants, and it was a 24 week, randomized, openlabel, comparator-controlled study that focused on glycemic control, body weight, and safety
with exenatide. Hgb A1C was measured from baseline to week 24 and in conclusion, Bydureon
resulted in superior glycemic control, with fewer side effects than Byetta did in patients with
type 2 diabetes (Blevins, et al., 2011).
Lastly, DURATION-6 study was the most recent study that was completed on exenatide.
This was a 26 week open-label, multicenter clinical study that compared Bydureon to Victoza
when administered at the maximum dosage. This study looked at Hgb A1C and results showed
that both treatment groups demonstrated a reduction in glucose and weight loss, but this trial did
not meet the prespecified primary endpoint that once-weekly injections of Exenatide were
noninferior to daily injections of Victoza (Buckley, 2011).
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Since Bydureon trials in DURATION studies have reported positive clinical outcomes,
Bydureon dosed once a week may be more convenient and as effective as other GLP-1 receptor
agonists. This research will provide information for the advanced practice nurse in a family care
setting to educate patients on making decisions as to the medication regimen for managing their
type 2 diabetes. This study determined the effectiveness of Bydureon as related to Hgb A1C and
BMI results over a 3 months period, from a small sample in a primary care setting. This aids the
advanced practice nurse in developing a successful treatment plan and provided knowledge on
Bydureon effectiveness.
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Chapter Three: Methodology
This chapter includes a description of the research design, the sample, and setting for the
study. Following is a discussion of the methods for data collection, tools for measurement,
statistical analysis and the protection of human subjects.
The purpose of this study was to examine the efficacy of Bydureon, once weekly dosage
in adults with type 2 diabetes. This descriptive, comparative, retrospective study evaluated the
medication efficacy by examining Hgb A1C and body mass index in adults with type 2 diabetes
at baseline, and then 3 months after Bydureon was prescribed. The research question was:
Do adult patients with type 2 diabetes who are started on the once weekly dosage of Bydureon
have an improved HGB A1C and BMI after a 3 month period?
Study Design
A descriptive, comparative, retrospective design comparing baseline to 3 month of Hgb
AIC and BMI was used to examine once weekly dosing of Bydureon in adults with type 2
diabetes. Outcomes measured were Hgb A1C and BMI.
Sample and Setting
Based on a power analysis, a convenience sample size of 35 patients over the age of 18
with type 2 diabetes who were started on the newly released GLP-1 were selected for this study.
This provided sufficient statistical power to determine large effect sizes in the two variables, Hgb
A1C and BMI by using a paired t-test (alpha=0.05; beta=0.2). Participants were recruited from a
local endocrinology clinic in northeast Florida.
Inclusion criteria were males and females with type 2 diabetes who are 18 years-of-age or
older, who have been on Bydureon for at least 90 days, with a Hgb A1C and BMI that were
recorded in their chart before they started on Bydureon and then 3 months after treatment was
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started. Exclusion criteria were any male or female with type 1 diabetes, any individual being
treated with insulin other than basal and brief course of short-acting insulin.
It was unknown in this study if these patients were newly diagnosed with type 2 diabetes,
the type 2 diabetes diagnosis date, and the exact reason why Bydureon was the medication of
choice for the particular participant.
Recruitment
Every clinical medical record where Bydureon was prescribed was reviewed for
inclusion and exclusion criteria. The physician and/or nurse practitioner at this individual clinic
advised the primary investigator when they ordered Bydureon for a patient and data collection
began with chart review to determine if they met both inclusion and exclusion criteria. If they
met both inclusion and exclusion criteria, then data collection began with a chart review. IRB
reviewed the study, it was deemed exempt. As this was a retrospective chart review, individual
consent was not necessary.
Procedures
Demographic data, information about use of Bydureon, and laboratory and
anthropological measurements were gathered. Demographic data included date of birth, gender,
and date Bydureon was started. All data was gathered and placed into a flow chart.
Retrospective chart review provided the laboratory data (Hgb A1C) and anthropological
measurements (height and weight). BMI was calculated based on the patient’s height and weight.
The location where the patient had their labs drawn for their Hgb A1C varied depending on their
insurance. The clinic has a contract with some insurance companies to draw labs in the office
and others were sent out to have their labs drawn, however, these details were not obtained on
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the individual participants. If labs were drawn outside of the clinic, the results were sent to the
clinic and then inserted into their computerized chart.
Data Collection
Data collection for this study was a retrospective medical chart review for the clinical
quantitative outcomes. When starting the initial data collection, the patient’s medical records
were reviewed by the investigator, retrospectively. Data were collected on a flow chart and kept
in a secure location without patient identifiers. A baseline Hgb A1C and BMI, as defined above
was calculated from weight and height measurements from the initial visit when the medication
was prescribed by the health care provider. Serial data was further obtained from records of the
patient’s at 3 month follow up visits after being started on Bydureon. These clinical outcomes
were also documented in a computerized spreadsheet by the investigator. Patients were
numbered one through thirty five.
Statistical Analysis Plan
Descriptive statistics were used to characterize the sample with respect to the lab and
demographic variables related to Bydureon use. A distribution analysis and change analysis were
performed and looked at age, baseline BMI, 3 month BMI, baseline Hgb A1C, and 3 month Hgb
A1C. A paired t-test was used to determine if there was a difference in before starting on
Bydureon and after 3 months of being on Bydureon, for both Hgb A1C and BMI.
Protection of Human Subjects
Data collected were held confidential and no names or personal information were
disclosed. Approval from the University of North Florida Institutional Review Board was
obtained prior to undertaking the study (see Appendix A). The study was deemed exempt by the
UNF IRB. When collecting Hgb A1C and BMI data, the medical record was identified by only a
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number and initials on a spreadsheet. Data were kept in a spreadsheet on a password coded
computer accessible only to the investigator.
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Chapter Four: Results
This chapter includes the statistical findings of this study. Demographic information is
first summarized. Following the demographic information, inferential statistics of the study are
presented.
As mentioned in chapter three, the purpose of this study was to examine the efficacy of
Bydureon, once weekly dosage in adults with type 2 diabetes. This descriptive, comparative,
retrospective study evaluated the effects of Bydureon by examining Hgb A1C and BMI in adults
with type 2 diabetes at baseline and then again 3 months after Bydureon is started. Participants
were from a local endocrinology clinic in northeast Florida. The retrospective chart reviews were
completed in 2013 at Northeast Florida Endocrine and Diabetes clinic in Jacksonville, Florida.
Characteristics of the Sample
Participants were 33 to 84 years old. All participants had been diagnosed with type 2
diabetes for at least 90 days but the exact duration of diabetes was not obtained. There were 17
males and 18 females that participated in this study, for a total of 35 participants. Demographic
data that was obtained was gender and age and is summarized in Table 4.1.
Descriptive Data Analysis
Lab data collected was BMI, baseline and at 3 months, and Hgb A1C, baseline and at 3
months. The BMI ranged from 21.58kg to 60.82kg at baseline and 21.48kg to 60.80kg at 3
months. The Hgb A1C ranged from 5.7 to 14.0 at baseline and 5.5 to 12.2 at 3 months (see
Appendix B). All but 7 subjects had a decrease in BMI. All but 7 subjects had a decrease in Hgb
A1C (see Table 4.3). Only one subject had an increase in both BMI and Hgb A1C at 3 months
after starting Bydureon. Only one subject dropped a whole category, from obese class I to
overweight. One patient was an outlier, and was classified as not overweight and had a normal
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BMI at baseline and 3 months. Three subjects Hgb A1C changed from high (>6.5%) to normal
(<6.5%) (see Table 4.2).
Table 4.1
Description of the Sample (n=35)
Characteristics
Gender
Female
Male
Age
30-39
40-49
50-59
60-69
70-79
80-89

N

%

18
17

51.4
48.6

2
7
12
10
3
1

5.71
20
34.28
28.57
8.57
2.85

N

%

Table 4.2
Description of Baseline Variables (n=35)
Baseline Variables
Hgb A1C
< 6.5%
> or = 6.5%
BMI
Not overweight
Overweight
Obese Class I
Obese Class II
Obese Class III

8
27

23
77

1
8
12
10
4

3
23
34
29
11
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Table 4.3
Hgb A1C Change (baseline to 3 months) (n=35)
Hgb A1C Change (baseline to 3 months)
Hgb A1C
High to normal
Same (high or normal, without worsen)
Normal to High
Worsened

N
3
25
0
7

%
9
71
0
20

A distribution analysis was completed to determine the distributions of age, baseline
BMI, 3 month BMI, baseline Hgb A1C, and 3 month Hgb A1C. A change analysis was
performed to determine the change from baseline to 3 months in both the BMI and Hgb A1C.
Figure 4.1

Figure 4.1.Age distribution of the participants from the study. Total of 35 participants. The
Average age was 56.6. Standard deviation was 10.07. Developed by Dr. Peter Wludyka,
Statistician.
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Table 4.4
Descriptive Statistics BMI and Hgb A1C(n=35)
M(SD)
BMI
Baseline
3 Months
Change

34.89(8.16)
34.52 (8.01)
-0.37(0.77)

M(SD)
Hgb A1C
Baseline
3 Months
Change

7.65 (1.61)
7.27(1.42)
-0.37(0.72)

Based on the distribution analysis and the analysis of change, the mean baseline BMI was
34.89. The mean 3 month BMI was 34.52. The change was a decrease of 0.37 in BMI from
baseline to 3 months after being on Bydureon. Anyone with a BMI greater than 30 is considered
obese. Both mean baseline and 3 month BMI are categorized as obesity class I according to the
Center for Disease Control and Prevention. Class I obesity is BMI 30 to 34.9. (CDC, 2014). The
mean baseline Hgb A1C was 7.65. The mean 3 month Hgb A1C was 7.27. The change was a
decrease of 0.37 in Hgb A1C from baseline to 3 months after being on Bydureon. (See Table
4.4). Both mean baseline and 3 months Hgb A1C are classified as high. The goal for a patient
with type 2 diabetes is a Hgb A1C less than 6.5%, according the American Association of
Clinical Endocrinologists and American College of Endocrinology (Handelsman et al., 2011).
Inferential Data Analysis
Paired t-tests
A paired t-test determines whether a sample of matched pairs of similar units differ from
each other in a significant way under the assumption that the paired differences are independent
and identically normally distributed. In this study, by comparing the same patients BMI and Hgb
A1C at baseline and 3 months into their Bydureon treatment, each patient was used as their own
control. There was no other control group used for this study. With a paired t-test, the statistical
power increases just because the random between-patient variation has been eliminated. The
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paired t-test shows statistical significance between baseline to 3 months in both BMI and Hgb
A1C on patients that are taking Bydureon. See Table 4.5 for paired t-test results for both BMI
and Hgb A1C.
Table 4.5
Paired T-test results: Difference baseline to 3 months (BMI and Hgb A1C)

Baseline M(SD)

3 month M(SD)

t(DF)

p

BMI

34.89(8.16)

34.52(8.01)

-2.86(34)

0.0072

Hgb A1C

7.64(1.61)

7.27(1.42)

-3.05(34)

0.0044

Note. t=paired t test.
Research Question
The research question was:
Do patients who are started on the once weekly dosage of Bydureon have an improved
Hgb A1C and BMI over a 3 month period?
Summary
After reviewing all of the descriptive and inferential statistical analysis it can be
concluded that there is a difference in the means of BMI and Hgb A1C over a 3 months period
for those on Bydureon. The results were statistically significant and this study showed that the
participants had a decrease in both BMI and Hgb A1C over a 3 months period while taking
Bydureon.
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Chapter Five: Discussion
This chapter provides a discussion of the results regarding BMI and Hgb A1C at
baseline and at 3 months in adults with type 2 diabetes after starting on the newer GLP-1
receptor agonist, Bydureon. Following this discussion, the limitations of the study will be
examined. After the limitations of the study, the implications for practice and recommendations
for future research will be provided.
Discussion
Results from this study do show a reduction in Hgb A1C and BMI in the majority of
patients that were taking Bydureon, after only three months of weekly doses. This indicates that
the medication has a positive effect on adult patients with type 2 diabetes. When compared to
other studies that have been done on Bydureon, the results to this study are very similar. The
DURATION-1 study was a three year study that showed patients receiving Bydureon
experienced a significant reduction in Hgb A1C (1.6 percentage points) and weight (5.1 pounds)
when compared to baseline (Buse, et al., 2010). With a longer duration to follow the participants
in this research study on the efficacy of Bydureon, it would be expected to have greater
outcomes like the DURATION-1 study. Compared to Lantus, the DURATION-3 study showed
that at 84 weeks, patients treated with Bydureon experience a significantly greater Hgb A1C
reduction from baseline as well as a weight loss while taking the medication versus the patients
that were on Lantus experienced a weight gain (Diamant, et al, 2010). This again is similar to
the results that were found in this study, when looking at Bydureon independently.
This study is clinically significant because there are a large number of individuals today
with type 2 diabetes. With the number of patients with type 2 diabetes on the rise, health care
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providers can use this information, knowing that this medication decreases Hgb A1C and BMI,
and use it when trying to find the appropriate diabetes treatment regimen for their patients.
Limitations
Although the study showed significant differences between HgbA1C and BMI when
taking Bydureon, several potential limitations warrant mention. Some of the limitations in this
study were medications, lifestyle, medical history and number of participants.
Medications
This study could have been improved if the patient’s complete medication list was
reviewed prior to accepting them to participate in the study. Certain medications that could have
had an impact on the participant’s results were medications such as weight loss medications,
steroids, and other diabetic medications. If a participant was taking a weight loss medication, the
results of the BMI would be not a good reflection as to the improvements of weight loss from
Bydureon alone. Another thing that could have been taken into consideration in this study was
compliance and adherence to therapy and/or proper use of medication, as this was not studied.
Lifestyle
This study could have been improved if patients’ lifestyles were taken into
consideration. Patients’ BMI and HgbA1C are both impacted greatly in their day to day living
and habits. Healthy eating habits and daily exercise may help to decrease or control patient’s
BMI and HgbA1C, as well many of the complications that are associated with type 2 diabetes.
Also, an individual’s level of stress could impact their BMI. Had all of these components been
assessed during this study, more accurate results could have been produced.
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Medical history
The only thing reviewed in the participants medical history was their diagnosis of type 2
diabetes. The date of type 2 diabetes diagnosis would have been beneficial to document on each
participants. A thorough medical history review to improve this study would have been
beneficial. Medical conditions that may have affected the results are history of bariatric surgery,
certain cancers, particularly pancreatic cancer and chronic GI complications.
Participant Number
Based on a power analysis, the minimum number of subjects I needed for this particular
study was 35 and the number of subjects was 35. With a larger sample size, there would have
been a stronger power, and therefore, more conclusive results with this study on the efficacy of
Bydureon.
Implications for Practice
It appears that Bydureon does have a positive effect on both Hgb A1C and BMI after
only three months. This is consistent with the research that compares this medication to other
medications on the market today. As practitioners, it is imperative that treatment of type 2
diabetes is not pharmaceuticals alone. Patients should be educated on healthy eating habits and
healthy doses of exercise because from the research that was done as well as other research on
type 2 diabetes, it is apparent that patients with type 2 diabetes are typically overweight or
obese. During dietary counseling, encouraging the patient to minimize carbohydrates would be
a helpful step in managing their type 2 diabetes. Patients need to be educated that their diabetes
medication is based on the amount of carbohydrates at each meal, therefore if the individual eats
more carbohydrates than they should, the diabetes medication will not be as effective and
therefore blood sugars may be uncontrolled. Creating your plate and being mindful of what you
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eat is a good step forward when trying to manage your blood sugars. Encouraging these patients
to keep a dietary log and record their meals would be a good way for patients to be more
mindful of what they are consuming as well as be able to share with their practitioners during
their visit in the clinic. Portion control would be vital to discuss with patients that have type 2
diabetes and are overweight or obese as well. The amount of food one eats is closely related to
their blood sugar control. Measuring foods would be important to review with patients with type
2 diabetes in order to manage portion control. If the patient is trying to lose weight and manage
their diabetes, as a practitioner, Bydureon may be a good selection for their diabetes
management. Twenty eight out of the thirty five participants in this study had a decrease in BMI
during a three month period after starting on Bydureon. The study does not reveal why the other
seven participants did not have a decrease in BMI. Twenty eight out of thirty five participants
also had a decrease in Hgb A1C in three months on Bydureon. The study does not reveal why
the other seven participants did not have a decrease in Hgb A1C. Compliance and medical
conditions would be worth looking into with these select participants that did not successfully
progress in their treatment as research has demonstrated in the past.
Bydureon is administered as a subcutaneous injection. With this being known, ease of
use is very important for practitioners to be aware of. Like similar medications for diabetes, for
example DPP-4 inhibitors, that are administered orally, the only route for Bydureon is via
subcutaneous injection. It is the practitioners’ responsibility to make sure the patient is
comfortable with administration of the medication. Bydureon is only administered once weekly,
unlike a patient taking oral form of medication for diabetes is responsible for taking it daily and
sometimes twice daily. Compared to the twice daily Byetta, Bydureon can be administered at
any time of the day and does not need to be administered with meals. Byetta is a pre-filled pen
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device and Bydureon is more complicated with a system that requires assembly. Practitioners
prescribing Bydureon must take this into consideration because people with vision problems or
limited manual dexterity may find Bydureon system difficult to assemble.
Future Research

In view of the complexity of type 2 diabetes and the current treatment regimens
available, more research needs to be done regarding appropriate treatment for individual
patients. This study can benefit patients with type 2 diabetes, as Bydureon is another treatment
option for available and this study provides some basic knowledge on the short-term
effectiveness of this medication. Future research that would be beneficial would be a study on
the ease of use of Bydureon to determine if patients are able to properly use the medication and
their comfort levels with the once weekly injection. This could be concluded by return
demonstration and personal surveys. Some information that would be beneficial to know
regarding ease of use would be if the patient had ever administered a subcutaneous injection
before, the patients feelings regarding preparation of Bydureon vial and syringe, do they
administer injection themselves and if so, ease of administering injection to self, how compliant
they are with administering their once weekly injection, have they ever missed doses, how they
learned how to administer their first Bydureon injection and any concerns or suggestions they
have regarding Bydureon injections. Incorporating patient’s lifestyle would be beneficial in
future Bydureon research since eating habits and exercise are a huge part of diabetes
management. Patients could be educated on health eating habits and exercise by their provider
and then be required to log their daily eating habits and exercise for the duration of the study
while they are taking Bydureon. Further research that would be beneficial in health care today
would be looking at patients on Bydureon with different medical conditions; such as HTN or
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hyperlipidemia and determine if the effectiveness of the medication with individuals with these
commonly diagnosed medical conditions. A multivariate study would be imperative to future
research by looking at more than one outcome, such as incorporating age, gender, and even
ethnicity to determine if they are statistically significantly in the outcome of patients taking
Bydureon.

Conclusion

Today, approximately 8.3% of the population in the United States have been diagnosed
with diabetes and that number is on the rise. The International Diabetes Federation Diabetes
Atlas is expecting the total number of individuals with type 2 diabetes to rise to 552 million by
2030 (Hilaire & Woods, 2013). Health care providers need to individualize the patients’ plans of
care to address multifactorials areas of their diabetes care and provide them with an opportunity
to successfully meet their goals. Practitioners must be knowledgeable about the treatment options
available, including the newer GLP-1 receptor agonist, Bydureon and its efficacy for adults with
type 2 diabetes. Based on the research question, patients started on weekly dosage of Bydureon
do have a statistically significant improvement in Hgb A1C and BMI over a 3 month period.
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IRB Approval Letter
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Appendix B
Data collection table:

#/
Inital
s

Type 2
Diabetic

Age/Ge
nder

Bydureon
Start Date

Baselin
e BMI

3
month
BMI

Baseline
Hgb A1C

3 month
Hgb A1C

1-S.L.

Yes

50/Male

5/20/2013

8.8

Yes

7/17/2012

5.9

5.8

3D.M.
4C.W.
5K.Q.
6D.W.
7-J.R.

Yes

36/Fema
le
48/femal
e
48/Male

8.3

7.7

8.3

8.5

5.8

5.7

6

6.1

8

8.2

8R.G.
9G.A.
10L.B.
11T.C.
12D.G.
13V.M.
14R.M.
15S.R.
16V.S.
17H.S.
18K.K.
19E.B.
20-

Yes

27.47kg
/m2
28.9kg/
m2
42.47kg
/m2
43.11kg
/m2
36.43kg
/m2
32.9kg/
m2
35.08kg
/m2
27.7kg/
m2
59.95kg
/m2
33.83kg
/m2
28.28kg
/m2
28.2kg/
m2
29.96kg
/m2
33.38kg
/m2
24.84kg
/m2
32.3kg/
m2
30.31kg
/m2
36.8kg/
m2
21.48kg
/m2
29.41kg

9.1

2-A.R.

27.38kg
/m2
28.9kg/
m2
43.26kg
/m2
46.51kg
/m2
36.56kg
/m2
33.41kg
/m2
36.21kg
/m2
28.87kg
/m2
60.14kg
/m2
34.51kg
/m2
28.5kg/
m2
28.35kg
/m2
30.79kg
/m2
32.69kg
/m2
25.45kg
/m2
31.46kg
/m2
30.71kg
/m2
36.48kg
/m2
21.58kg
/m2
29.41kg

6.7

6.2

7.3

6.2

7.5

7.2

11.1

9.5

8.4

6.9

6.3

5.9

6

6.3

6

5.8

5.7

5.5

6.7

6.5

7.2

6.5

14

12.2

7.9

8

Yes
Yes

10/29/2012
2/4/2013

47/Fema
le
51/Male

11/2/2012

59/Fema
le
61/Fema
le
57/Male

10/16/2012

11/26/2012

Yes

46/Fema
le
63/Male

Yes

48/Male

4/1/2013

Yes

55/Fema
le
65/Male

2/1/2013

Yes
Yes

Yes
Yes

Yes
Yes

Yes

57/Fema
le
66/Fema
le
84/Fema
le
63/Fema
le
61/Male

Yes

55/Male

Yes
Yes
Yes

4/3/2013

6/19/2012
3/21/2013

4/11/2013

1/17/2013
9/7/2012
11/19/2012
1/4/2013
4/5/2012
3/12/2013
3/4/2013
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S.P.
21C.B.
22M.C.
23B.W.
24J.W.
25C.F.
26W.M.
27A.L.
28R.R.
29H.H.
30D.L.
31J.M.
32V.B.
33H.R.
34F.B.
35S.G.

Yes

2/26/2013

Yes

49/Fema
le
71/Male

Yes

59/Male

2/26/2013

Yes

3/7/2012

10/31/2012

Yes

60/Fema
le
59/Fema
le
60/Fema
le
62/Fema
le
33/Male

Yes

70/Male

3/19/2012

Yes

62/Male

2/14/2013

Yes

70/Male

10/16/2012

Yes

54/Male

11/2/2012

Yes

43/Fema
le
53/Male

10/4/2012

56/Fema
le

2/26/2013

Yes
Yes
Yes

Yes
Yes

3/7/2013

1/9/2013

11/5/2012
8/21/2012

11/2/2012

/m2
38.77kg
/m2
60.82kg
/m2
33.51kg
/m2
35.61kg
/m2
38.09kg
/m2
32.12kg
/m2
31.64kg
/m2
31.06kg
/m2
38.74kg
/m2
29.95kg
/m2
31.53kg
/m2
36.93kg
/m2
31.41kg
/m2
40.02kg
/m2
39.89kg
/m2

/m2
38.49kg
/m2
60.80kg
/m2
33.25kg
/m2
34.19kg
/m2
37.73kg
/m2
32.12kg
/m2
32.42kg
/m2
31.33kg
/m2
38.6kg/
m2
29.79kg
/m2
30.89kg
/m2
36.48kg
/m2
31.41kg
/m2
39.82kg
/m2
38.12kg
/m2

7.2

7

6.7

6.5

7.2

6.9

7.6

6.4

7.6

9.7

8.1

7.2

9.2

8.9

7.6

7.6

8.9

7

6.9

6.7

6.2

5.5

7.4

7.2

8.4

8

7.6

7.9

8.8

8.6
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Appendix C
Acceptance letter from Dr. Segal at Northeast Florida Endocrine and Diabetes Associates,
P.A.

August 10, 2013

Scott A. Segel, M.D., F.A.C.E.
Northeast Florida Endocrine and Diabetes Associates, P.A.
3550 University Blvd. Suite 301
Jacksonville, Florida 32216
Phone #: (904) 384-2240

Dear University of North Florida Institutional Review Board,
I am granting permission to Katie Fetter, RN, BSN, (University of North FloridaFamily Nurse Practitioner student), to complete her research study at my medical
practice. I understand that her research study, Efficacy of Bydureon in Type 2
Diabetic Patients, must first be approved by the University of North Florida IRB.
Ms. Fetter will have access to patients and to their clinical data for her
retrospective chart review. Informed consent is not needed for this study.
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